Cargando…

Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice

SIMPLE SUMMARY: Although comprehensive genomic profiling (CGP) tests have been covered under the Japanese national health insurance program, the utility and issues of CGP tests have not been clarified. We retrospectively reviewed 115 patients with incurable pancreatic cancer (IPC) who underwent CGP...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamai, Takuo, Ikezawa, Kenji, Sugimoto, Naotoshi, Urabe, Makiko, Kai, Yugo, Takada, Ryoji, Nakabori, Tasuku, Uehara, Hiroyuki, Kawamura, Takahisa, Kunimasa, Kei, Yamamoto, Sachiko, Wakamatsu, Toru, Hayashi, Takuji, Kukita, Yoji, Fujisawa, Fumie, Inoue, Tazuko, Yamaguchi, Yuko, Yamasaki, Tomoyuki, Honma, Keiichiro, Ohkawa, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913675/
https://www.ncbi.nlm.nih.gov/pubmed/36765927
http://dx.doi.org/10.3390/cancers15030970
_version_ 1784885484161335296
author Yamai, Takuo
Ikezawa, Kenji
Sugimoto, Naotoshi
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Nakabori, Tasuku
Uehara, Hiroyuki
Kawamura, Takahisa
Kunimasa, Kei
Yamamoto, Sachiko
Wakamatsu, Toru
Hayashi, Takuji
Kukita, Yoji
Fujisawa, Fumie
Inoue, Tazuko
Yamaguchi, Yuko
Yamasaki, Tomoyuki
Honma, Keiichiro
Ohkawa, Kazuyoshi
author_facet Yamai, Takuo
Ikezawa, Kenji
Sugimoto, Naotoshi
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Nakabori, Tasuku
Uehara, Hiroyuki
Kawamura, Takahisa
Kunimasa, Kei
Yamamoto, Sachiko
Wakamatsu, Toru
Hayashi, Takuji
Kukita, Yoji
Fujisawa, Fumie
Inoue, Tazuko
Yamaguchi, Yuko
Yamasaki, Tomoyuki
Honma, Keiichiro
Ohkawa, Kazuyoshi
author_sort Yamai, Takuo
collection PubMed
description SIMPLE SUMMARY: Although comprehensive genomic profiling (CGP) tests have been covered under the Japanese national health insurance program, the utility and issues of CGP tests have not been clarified. We retrospectively reviewed 115 patients with incurable pancreatic cancer (IPC) who underwent CGP tests in a Japanese cancer referral center from November 2019 to August 2021. Eight cases (6.9%) were diagnosed as tumor mutation burden-high and/or microsatellite instability-high. The gene mutation rates of KRAS/TP53/CDKN2A/SMAD4 were 93.0/83.0/53.0/25.2%, respectively. Twenty-five patients (21.7%) had homologous recombination deficiency (HRD)-related genetic mutations. Six patients (5.2%) underwent gene-matched therapy based on results of CGP tests. The median overall survival (OS) was significantly longer in the HRD (+) group. In multivariate analysis, HRD-related gene mutation was an independent prognostic factor associated with favorable OS. CGP tests for patients with IPC have the potential utility of detecting HRD-related gene mutations as prognostic factors as well as a therapeutic search. ABSTRACT: Although comprehensive genomic profiling (CGP) tests have been covered under the Japanese national health insurance program since 2018, the utility and issues of CGP tests have not been clarified. We retrospectively reviewed 115 patients with incurable pancreatic cancer (IPC) who underwent CGP tests in a Japanese cancer referral center from November 2019 to August 2021. We evaluated the results of CGP tests, treatments based on CGP tests, and survival time. Eight cases (6.9%) were diagnosed as tumor mutation burden-high (TMB-H) and/or microsatellite instability-high (MSI-H). The gene mutation rates of KRAS/TP53/CDKN2A/SMAD4 were 93.0/83.0/53.0/25.2%, respectively. Twenty-five patients (21.7%) had homologous recombination deficiency (HRD)-related genetic mutations. Four patients (3.5%) having TMB-H and/or MSI-H were treated with pembrolizumab, and only two patients (1.7%) participated in the clinical trials. Patient characteristics were not significantly different between patients with and without HRD-related gene mutations. The median OS was significantly longer in the HRD (+) group than in the HRD (−) group (749 days vs. 519 days, p = 0.047). In multivariate analysis, HRD-related gene mutation was an independent prognostic factor associated with favorable OS. CGP tests for patients with IPC have the potential utility of detecting HRD-related gene mutations as prognostic factors as well as a therapeutic search.
format Online
Article
Text
id pubmed-9913675
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99136752023-02-11 Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice Yamai, Takuo Ikezawa, Kenji Sugimoto, Naotoshi Urabe, Makiko Kai, Yugo Takada, Ryoji Nakabori, Tasuku Uehara, Hiroyuki Kawamura, Takahisa Kunimasa, Kei Yamamoto, Sachiko Wakamatsu, Toru Hayashi, Takuji Kukita, Yoji Fujisawa, Fumie Inoue, Tazuko Yamaguchi, Yuko Yamasaki, Tomoyuki Honma, Keiichiro Ohkawa, Kazuyoshi Cancers (Basel) Article SIMPLE SUMMARY: Although comprehensive genomic profiling (CGP) tests have been covered under the Japanese national health insurance program, the utility and issues of CGP tests have not been clarified. We retrospectively reviewed 115 patients with incurable pancreatic cancer (IPC) who underwent CGP tests in a Japanese cancer referral center from November 2019 to August 2021. Eight cases (6.9%) were diagnosed as tumor mutation burden-high and/or microsatellite instability-high. The gene mutation rates of KRAS/TP53/CDKN2A/SMAD4 were 93.0/83.0/53.0/25.2%, respectively. Twenty-five patients (21.7%) had homologous recombination deficiency (HRD)-related genetic mutations. Six patients (5.2%) underwent gene-matched therapy based on results of CGP tests. The median overall survival (OS) was significantly longer in the HRD (+) group. In multivariate analysis, HRD-related gene mutation was an independent prognostic factor associated with favorable OS. CGP tests for patients with IPC have the potential utility of detecting HRD-related gene mutations as prognostic factors as well as a therapeutic search. ABSTRACT: Although comprehensive genomic profiling (CGP) tests have been covered under the Japanese national health insurance program since 2018, the utility and issues of CGP tests have not been clarified. We retrospectively reviewed 115 patients with incurable pancreatic cancer (IPC) who underwent CGP tests in a Japanese cancer referral center from November 2019 to August 2021. We evaluated the results of CGP tests, treatments based on CGP tests, and survival time. Eight cases (6.9%) were diagnosed as tumor mutation burden-high (TMB-H) and/or microsatellite instability-high (MSI-H). The gene mutation rates of KRAS/TP53/CDKN2A/SMAD4 were 93.0/83.0/53.0/25.2%, respectively. Twenty-five patients (21.7%) had homologous recombination deficiency (HRD)-related genetic mutations. Four patients (3.5%) having TMB-H and/or MSI-H were treated with pembrolizumab, and only two patients (1.7%) participated in the clinical trials. Patient characteristics were not significantly different between patients with and without HRD-related gene mutations. The median OS was significantly longer in the HRD (+) group than in the HRD (−) group (749 days vs. 519 days, p = 0.047). In multivariate analysis, HRD-related gene mutation was an independent prognostic factor associated with favorable OS. CGP tests for patients with IPC have the potential utility of detecting HRD-related gene mutations as prognostic factors as well as a therapeutic search. MDPI 2023-02-03 /pmc/articles/PMC9913675/ /pubmed/36765927 http://dx.doi.org/10.3390/cancers15030970 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamai, Takuo
Ikezawa, Kenji
Sugimoto, Naotoshi
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Nakabori, Tasuku
Uehara, Hiroyuki
Kawamura, Takahisa
Kunimasa, Kei
Yamamoto, Sachiko
Wakamatsu, Toru
Hayashi, Takuji
Kukita, Yoji
Fujisawa, Fumie
Inoue, Tazuko
Yamaguchi, Yuko
Yamasaki, Tomoyuki
Honma, Keiichiro
Ohkawa, Kazuyoshi
Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice
title Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice
title_full Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice
title_fullStr Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice
title_full_unstemmed Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice
title_short Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice
title_sort utility of comprehensive genomic profiling tests for patients with incurable pancreatic cancer in clinical practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913675/
https://www.ncbi.nlm.nih.gov/pubmed/36765927
http://dx.doi.org/10.3390/cancers15030970
work_keys_str_mv AT yamaitakuo utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT ikezawakenji utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT sugimotonaotoshi utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT urabemakiko utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT kaiyugo utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT takadaryoji utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT nakaboritasuku utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT ueharahiroyuki utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT kawamuratakahisa utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT kunimasakei utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT yamamotosachiko utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT wakamatsutoru utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT hayashitakuji utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT kukitayoji utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT fujisawafumie utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT inouetazuko utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT yamaguchiyuko utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT yamasakitomoyuki utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT honmakeiichiro utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice
AT ohkawakazuyoshi utilityofcomprehensivegenomicprofilingtestsforpatientswithincurablepancreaticcancerinclinicalpractice